Analyst Ratings For Array Biopharma Inc (NASDAQ:ARRY)
Today, Array Biopharma Inc (NASDAQ:ARRY) stock was downgraded by Leerink Swann from Outperform to Market Perform.
There are 6 Hold Ratings, 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Array Biopharma Inc (NASDAQ:ARRY) is Hold with a consensus target price of $31.1111 per share, a potential 33.01% downside.
Some recent analyst ratings include
- 6/18/2019-Array Biopharma Inc (NASDAQ:ARRY) gets downgraded to Market Perform by Leerink Swann
- 6/17/2019-Array Biopharma Inc (NASDAQ:ARRY) gets downgraded to Hold by Jefferies Financial Group
- 6/17/2019-Array Biopharma Inc (NASDAQ:ARRY) gets downgraded to Neutral by Piper Jaffray Companies
- 6/17/2019-Array Biopharma Inc (NASDAQ:ARRY) gets downgraded to Hold by SunTrust Banks
- 6/17/2019-Array Biopharma Inc (NASDAQ:ARRY) gets downgraded to Market Perform by Wells Fargo & Co
- On 6/3/2019 Victor Sandor, Insider, sold 36,134 with an average share price of $27.58 per share and the total transaction amounting to $996,575.72.
- On 5/30/2019 Victor Sandor, Insider, sold 15,728 with an average share price of $27.50 per share and the total transaction amounting to $432,520.00.
- On 5/28/2019 Victor Sandor, Insider, sold 74,915 with an average share price of $27.00 per share and the total transaction amounting to $2,022,705.00.
- On 5/23/2019 Victor Sandor, Insider, sold 40,634 with an average share price of $26.50 per share and the total transaction amounting to $1,076,801.00.
- On 5/21/2019 Victor Sandor, Insider, sold 12,600 with an average share price of $26.50 per share and the total transaction amounting to $333,900.00.
- On 2/19/2019 Carrie Smith Cox, Director, bought 5,000 with an average share price of $23.20 per share and the total transaction amounting to $116,000.00.
- On 2/7/2019 Jason Haddock, CFO, sold 96,712 with an average share price of $21.80 per share and the total transaction amounting to $2,108,321.60.
About Array Biopharma Inc (NASDAQ:ARRY)
Array BioPharma Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer and other diseases in North America, Europe, and the Asia Pacific. It provides BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF mutation. Read More…
Recent Trading Activity for Array Biopharma Inc (NASDAQ:ARRY)
Shares of Array Biopharma Inc closed the previous trading session at 46.44 up +16.85 56.94% with 45.67 shares trading hands.